AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25628520 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study 25629445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate HYPO score
Number of subjects: 152
Study 25629445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate Lability Index (LI)
Number of subjects: 152
Study 25629445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate mean amplitude of glycemic excursion (MAGE)
Number of subjects: 152
Study 25629445 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) worn for 72 hours
Number of subjects: 152
Study 25629663 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (1×10(10) viral particles)
Number of subjects: 60
Study 25629663 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (2.5×10(10) viral particles)
Number of subjects: 60
Study 25629663 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (5×10(10) viral particles)
Number of subjects: 60
Study 25629663 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine followed by MVA booster
Number of subjects: 60
Study 25629663 — intervention group
Group type: COMPARATOR
Intervention: ChAd3 vaccine
Number of subjects: 60
Study 25630297 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine-ofatumumab
Number of subjects: 49
Study 25630494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid valve morphology (n=57)
Number of subjects: 120
Study 25630494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid valve morphology (n=61)
Number of subjects: 120
Study 25630964 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian males
Number of subjects: 554
Study 25630964 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 554
Study 25630964 — intervention group
Group type: COMPARATOR
Intervention: Caucasian males and AA males
Number of subjects: 554
Study 25630964 — intervention group
Group type: COMPARATOR
Intervention: Females compared to males
Number of subjects: 554
Study 25631114 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-duodeno-jejunal bypass sleeve (GJBS) implanted for 12 months
Number of subjects: 13
Study 25631316 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducible chest wall tenderness (CWT) on palpation
Number of subjects: 121
Study 25631316 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reproducible chest wall tenderness (CWT)
Number of subjects: 121
Study 25631349 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR)
Number of subjects: 233
Study 25631349 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 233
Study 25631349 — intervention group
Group type: COMPARATOR
Intervention: Normal weight with higher WHR
Number of subjects: 233
Study 25631349 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis for WHR
Number of subjects: 233
Study 25631362 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mindfulness therapy
Number of subjects: 0
Study 25632070 — intervention group
Group type: EXPERIMENTAL
Intervention: SB939 (60 mg/day every other day for 3 of 4 weeks)
Number of subjects: 22
Study 25633134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 1211
Study 25633134 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (titrated doses)
Number of subjects: 1211
Study 25633190 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation and Flutter Outcome Risk Determination decision aid
Number of subjects: 497
Study 25633714 — intervention group
Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with mild hepatic impairment
Number of subjects: 26
Study 25633714 — intervention group
Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with moderate hepatic impairment
Number of subjects: 26
Study 25633714 — intervention group
Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with severe hepatic impairment
Number of subjects: 26
Study 25633714 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 26
Study 25633714 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe hepatic impairment
Number of subjects: 26
Study 25633714 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 26
Study 25633805 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiology questionnaire (voluntary)
Number of subjects: 617
Study 25633882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5-mg
Number of subjects: 43
Study 25633882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0-mg
Number of subjects: 43
Study 25634000 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO care
Number of subjects: 6182
Study 25634000 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 6182
Study 25634207 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 116
Study 25634486 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided dual through-the-needle imaging (cystoscopy and nCLE)
Number of subjects: 30
Study 25634486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Number of subjects: 30
Study 25634486 — intervention group
Group type: EXPERIMENTAL
Intervention: nCLE
Number of subjects: 30
Study 25634486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cystoscopy and nCLE
Number of subjects: 30
Study 25634628 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care and communication from ICU staff
Number of subjects: 145
Study 25634628 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of post-traumatic stress disorder, anxiety, and depression in relatives
Number of subjects: 145
Study 25634628 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives' satisfaction with medical care and communication
Number of subjects: 145
Study 25634727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 1
Study 25634727 — intervention group
Group type: COMPARATOR
Intervention: MRgx200B;HIFU device
Number of subjects: 1
Study 25635138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg daily)
Number of subjects: 18
Study 25635704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 0
Study 25635704 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 25636046 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate (TE)
Number of subjects: 15
Study 25637055 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT-SM6 (0.3, 1, 3, and 6 mg/kg)
Number of subjects: 12
Study 25637377 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 20
Study 25637379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen with granulocyte colony-stimulating factor support followed by weekly paclitaxel
Number of subjects: 11
Study 25637379 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel
Number of subjects: 11
Study 25637379 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 11
Study 25637379 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 11
Study 25637379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-density regimen with FEC followed by weekly paclitaxel
Number of subjects: 11
Study 25638754 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-forward randomization with block urn design
Number of subjects: 0
Study 25638754 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization method with imbalance control threshold and biased coin probability
Number of subjects: 0
Study 25638805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 881
Study 25639506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² every 3 weeks with prednisolone 10 mg daily for up to 10 cycles
Number of subjects: 112
Study 25640580 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 33
Study 25641086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS) decrease
Number of subjects: 425
Study 25641086 — intervention group
Group type: COMPARATOR
Intervention: Baroreflex sensitivity (BRS) stable
Number of subjects: 425
Study 25641401 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal Fistula Plug (AFP)
Number of subjects: 71
Study 25641401 — intervention group
Group type: COMPARATOR
Intervention: Endorectal Advancement Flap (ERAF)
Number of subjects: 71
Study 25641532 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRISM consent documents
Number of subjects: 1117
Study 25641662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily in 6-week cycles: 4 weeks on treatment, 2 weeks off treatment)
Number of subjects: 1124
Study 25642145 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg dose
Number of subjects: 12
Study 25642145 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 12
Study 25642295 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referred participants (SRPs)
Number of subjects: 795
Study 25642295 — intervention group
Group type: COMPARATOR
Intervention: Actively recruited participants (ARPs)
Number of subjects: 795
Study 25642392 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multimodal MRI follow-up including diffusion tensor imaging (DTI), perfusion imaging, FLAIR, and contrast-enhanced 3D T1-weighted MR.
Number of subjects: 5
Study 25642774 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk individuals who progressed to T1D
Number of subjects: 54
Study 25642774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subjects
Number of subjects: 54
Study 25642774 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of insulin secretory kinetics
Number of subjects: 54
Study 25642774 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test measuring unmethylated INS DNA
Number of subjects: 54
Study 25642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster A (milder disease)
Number of subjects: 2164
Study 25642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster B (less systemic inflammation at baseline)
Number of subjects: 2164
Study 25642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster C (many comorbidities, evidence of systemic inflammation)
Number of subjects: 2164
Study 25642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster D (low FEV1, severe emphysema)
Number of subjects: 2164
Study 25642832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster E (intermediate for most variables)
Number of subjects: 2164
Study 25643053 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoSet (MyoGrip, MyoPinch, MoviPlate)
Number of subjects: 53
Study 25643053 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoGrip and MyoPinch
Number of subjects: 53
Study 25643053 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure
Number of subjects: 53
Study 25644336 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in the SCARB1 gene (rs1672879)
Number of subjects: 2581
Study 25644336 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in the SLIT3 gene
Number of subjects: 2581
Study 25644336 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in the DHRS2 gene
Number of subjects: 2581
Study 25644339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus EAA feeding (15 g mixed-EAA as a single dose)
Number of subjects: 16
Study 25644339 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread EAA feeding (15 g mixed-EAA in 4 fractions at 45-min intervals)
Number of subjects: 16
Study 25644488 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescopic extraperitoneal dissection
Number of subjects: 153
Study 25644488 — intervention group
Group type: COMPARATOR
Intervention: Balloon dissection
Number of subjects: 153
Study 25644659 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mm cryoballoon ablation
Number of subjects: 21
Study 25644958 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimerism-based immunotherapy (IT) with fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI)
Number of subjects: 43
Study 25644958 — intervention group
Group type: COMPARATOR
Intervention: Full donor chimerism (FDC)
Number of subjects: 43
Study 25644958 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimerism-based immunotherapy (IT)
Number of subjects: 43
Study 25644958 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 43
Study 25644958 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 43
Study 25645025 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus, intranasally inoculated at increasing doses (up to 3.5 × 10(6) TCID50)
Number of subjects: 29
Study 25645025 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus, highest dose (3.5 × 10(6) TCID50)
Number of subjects: 29
Study 25645025 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/California/2009 (H1N1) virus
Number of subjects: 29
Study 25645240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiebreaker algorithm using 3 rapid diagnostic tests (RDTs) in series
Number of subjects: 2620
Study 25645240 — intervention group
Group type: COMPARATOR
Intervention: Serial algorithm with 2 RDTs followed by a confirmation test
Number of subjects: 2620
Study 25645240 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of the Orgenics Immunocomb Combfirm® (OIC) confirmation test to either algorithm
Number of subjects: 2620
Study 25645240 — intervention group
Group type: EXPERIMENTAL
Intervention: Weakly reactive test lines
Number of subjects: 2620
Study 25645263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab-dexamethasone (O-Dex) regimen
Number of subjects: 33
Study 25645660 — intervention group
Group type: EXPERIMENTAL
Intervention: IV voriconazole (8.1±2.1 mg/kg/day)
Number of subjects: 10
Study 25645660 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 10
Study 25645660 — intervention group
Group type: EXPERIMENTAL
Intervention: SBECD (129±33 mg/kg/day)
Number of subjects: 10
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Life support
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort measures only
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain treatment preferences
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor communication about treatment options
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-sustaining treatments for more than 7 days
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with nurses
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with decision-making process
Number of subjects: 535
Study 25645668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of control over care
Number of subjects: 535
Study 25645847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0
Study 25645847 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant telaprevir use, inosine triphosphatase genetics, creatinine clearance, weight, and sex
Number of subjects: 0
Study 25646327 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI increase (1-kg/m²)
Number of subjects: 826
Study 25646327 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted GWG increase (0.1-kg/wk)
Number of subjects: 826
Study 25646327 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed GWG exceeding recommendations
Number of subjects: 826
Study 25646336 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls
Number of subjects: 402
Study 25646793 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 50
Study 25646793 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 50
Study 25647532 — intervention group
Group type: EXPERIMENTAL
Intervention: Class C (n=144; 86% sporadic, 9% short, 5% medium-to-long bouts)
Number of subjects: 396
Study 25647532 — intervention group
Group type: EXPERIMENTAL
Intervention: Class B (n=174; 93% sporadic, 5% short, 2% medium-to-long bouts)
Number of subjects: 396
Study 25647532 — intervention group
Group type: COMPARATOR
Intervention: Class A (n=78; 97% sporadic, 2% short, 1% medium-to-long bouts)
Number of subjects: 396
Study 25647655 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology majors
Number of subjects: 247
Study 25647655 — intervention group
Group type: COMPARATOR
Intervention: Non-kinesiology majors
Number of subjects: 247
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity physical activity (higher-light intensity)
Number of subjects: 1130
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity physical activity (lower-light intensity)
Number of subjects: 1130
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (time spent watching television)
Number of subjects: 1130
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (reading and computer use)
Number of subjects: 1130
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (both objectively assessed and self-reported)
Number of subjects: 1130
Study 25647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (lower sedentary times)
Number of subjects: 1130
Study 25648230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 12 mmHg (Group M)
Number of subjects: 40
Study 25648230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 15 mmHg (Group H)
Number of subjects: 40
Study 25648230 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 40
Study 25648230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with intra-abdominal pressure of 9 mmHg (Group L)
Number of subjects: 40
Study 25648230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 40
Study 25648299 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly vinorelbine and oxaliplatin (NVBOX) given every 4 weeks for a maximum of 6 cycles.
Number of subjects: 44
Study 25648299 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly vinorelbine and oxaliplatin (NVBOX)
Number of subjects: 44
Study 25648341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment
Number of subjects: 129
Study 25648341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment for approximately 6 months
Number of subjects: 129
Study 25648341 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, nonectatic subjects)
Number of subjects: 129
Study 25648779 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal characteristics including genetic, physiologic response to pregnancy, and environmental factors
Number of subjects: 10037
Study 25648779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy ending at <37+0 weeks' gestation
Number of subjects: 10037
Study 25649171 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvirion H3N2v vaccine (15 µg of hemagglutinin/dose), administered in 2 doses 21 days apart.
Number of subjects: 188
Study 25649350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 90
Study 25650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 52
Study 25650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film thickness (TFT) measured with optical coherence tomography (OCT)
Number of subjects: 52
Study 25650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OSDI and TFT
Number of subjects: 52
Study 25650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film thickness (TFT)
Number of subjects: 52
Study 25650419 — intervention group
Group type: EXPERIMENTAL
Intervention: Other evaluated signs of DES
Number of subjects: 52
Study 25650684 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Alliance
Number of subjects: 400
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-control drugs
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: VKA use
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic scores
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic scores
Number of subjects: 1072
Study 25651449 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anticoagulant therapy
Number of subjects: 1072
Study 25651489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild disease (native livers and no portal hypertension)
Number of subjects: 269
Study 25651489 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disease (with portal hypertension or post-liver transplant)
Number of subjects: 269
Study 25651489 — intervention group
Group type: EXPERIMENTAL
Intervention: Native livers with portal hypertension
Number of subjects: 269
Study 25651489 — intervention group
Group type: COMPARATOR
Intervention: Native livers without portal hypertension
Number of subjects: 269
Study 25651730 — intervention group
Group type: EXPERIMENTAL
Intervention: UMSC transfusion
Number of subjects: 18
Study 25651830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) + Dexamethasone (20 mg for 2 days with each Bz dose)
Number of subjects: 100